Archives de l’auteur : Marianne Duparc

Lyon – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled « the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine. »

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ». 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ». 

Lille – Oral PresentationFlorence Nicolas, Director of R&D and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza vaccine candidate: Short-term results of the Phase 1 clinical trial ».

Boston – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».

Barcelona – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».

Singapore – Oral Presentations and PostersAlexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ». Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present « Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human …

Continuer la lecture « OPTIONS X »

Edinburgh – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled « OVX836 protects mice in lethal challenges with multiples strains of influenza A viruses ».

Beijing – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present preclinical results of OVX836 as part of a poster entitled « OVX836 a multimerized nucleoprotein based vaccine candidate protects mice against lethal challenges of multiple strains of influenza A viruses ».

Lausanne – Oral PresentationDr. Fergal Hill, Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled « OVX836, a multimerized nucleoprotein (NP) induces cellular responses against NP in various animal models challenges of multiple strains of influenza A viruses ».